Future Therapies of Wet Age-Related Macular Degeneration
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Age-related macular degeneration (AMD) is the leading cause of blindness in the elderly population, and the prevalence of the disease increases exponentially with every decade after the age of 50 years. While VEGF inhibitors are promising drugs for treating patients with ocular neovascularization, there are limitations to their potential for improving vision in AMD patients. Thus, future therapies are required to have the potential to improve visual outcomes. This paper will summarize the future strategies and therapeutic targets that are aimed at enhancing the efficacy and duration of effect of antiangiogenic strategies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Extracellular Matrix: Not Just Pretty Fibrils
Hynes, R. O. (2009) · Science · doi:10.1126/science.1176009 · Cited by 3,527
Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration
Brown, D. M., Kaiser, P. K., Michels, M., Soubrane, G., Heier, J. S., Kim, R. Y., Sy, J. P., & Schneider, S. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062655 · Cited by 3,522
Regulation of Immune Responses by mTOR
Powell, J. D., Pollizzi, K. N., Heikamp, E. B., & Horton, M. R. (2012) · Annual Review of Immunology · doi:10.1146/annurev-immunol-020711-075024 · Cited by 836
Complement C3 variant and the risk of age-related macular degeneration
Yates, J. R. W., Sepp, T., Matharu, B. K., Khan, J. C., Thurlby, D. A., Shahid, H., Clayton, D. G., Hayward, C., Morgan, J., Wright, A. F., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072618 · Cited by 829 · cited 1×
“C3 induces VEGF expression in vivo and in vitro, and C3 gene polymorphism increases the risk of AMD [30].”
BackgroundAnderson, D. H., Radeke, M. J., Gallo, N. B., Chapin, E. A., Johnson, P. T., Curletti, C. R., Hancox, L. S., Hu, J., Ebright, J. N., Malek, G., et al. (2010) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2009.11.003 · Cited by 727
Variation in complement factor 3 is associated with risk of age-related macular degeneration
Maller, J. B., Fagerness, J. A., Reynolds, R. C., Neale, B. M., Daly, M. J., & Seddon, J. M. (2007) · Nature Genetics · doi:10.1038/ng2131 · Cited by 437 · cited 1×
“Genetic studies revealed highly significant statistical associations between AMD and variants of C3 gene [27–30].”
BackgroundA prospective study of cigarette smoking and age-related macular degeneration in women
Seddon, J. M. (1996) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1996.03540140029022 · Cited by 435
Finnemann, S. C., Bonilha, V. L., Marmorstein, A. D., & Rodriguez-Boulan, E. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.24.12932 · Cited by 382
A Prospective Study of Cigarette Smoking and Risk of Age-Related Macular Degeneration in Men
Christen, W. G. (1996) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1996.03540140035023 · Cited by 320 · cited 2×
“Recently, it has been reported that PEDF protein expression was decreased in RPE from smoker patients with AMD compared with controls [63].”
BackgroundLoss of synchronized retinal phagocytosis and age-related blindness in mice lacking αvβ5 integrin
Nandrot, E. F., Kim, Y., Brodie, S. E., Huang, X., Sheppard, D., & Finnemann, S. C. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20041447 · Cited by 319
Photoreceptor degeneration and dysfunction in aging and age-related maculopathy
Jackson, G. R., Owsley, C., & Curcio, C. A. (2002) · Ageing Research Reviews · doi:10.1016/s1568-1637(02)00007-7 · Cited by 317 · cited 1×
“These changes would be predicted to decrease the supply of oxygen, nutrients, and growth factors to the cells from the choroidal or retinal vessels and inhibit the phagocytosis of photoreceptor outer segments [44].”
BackgroundComplement Component C3 and Risk of Age-Related Macular Degeneration
Despriet, D. D. G., van Duijn, C. M., Oostra, B. A., Uitterlinden, A. G., Hofman, A., Wright, A. F., ten Brink, J. B., Bakker, A., de Jong, P. T. V. M., Vingerling, J. R., et al. (2009) · Ophthalmology · doi:10.1016/j.ophtha.2008.09.055 · Cited by 94
Cited by
Kinase inhibitors: the road ahead
Ferguson, F. M., & Gray, N. S. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.21 · Cited by 1,009
Holz, F. G., Dugel, P. U., Weissgerber, G., Hamilton, R., Silva, R., Bandello, F., Larsen, M., Weichselberger, A., Wenzel, A., Schmidt, A., et al. (2016) · Ophthalmology · doi:10.1016/j.ophtha.2015.12.030 · Cited by 184
Lode, H. E., Gjølberg, T. T., Foss, S., Sivertsen, M. S., Brustugun, J., Andersson, Y., Jørstad, Ø. K., Moe, M. C., & Andersen, J. T. (2019) · Scientific Reports · doi:10.1038/s41598-019-54226-7 · Cited by 40
Metadata
- Authors
- Ishikawa, M., Jin, D., Sawada, Y., Abe, S., & Yoshitomi, T.
- Venue
- Journal of Ophthalmology
- Publisher
- Wiley
- Published
- 2015
- Volume
- 2015
- Pages
- 1-10
- ISSN
- 2090-004X (ISSN-L)
- 2090-0058
- OpenAlex
- W1999610747
- Cited by
- 54
- References
- 12
- FWCI
- 5.50
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.